These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1020 related articles for article (PubMed ID: 30258889)

  • 1. Temozolomide resistance in glioblastoma multiforme.
    Lee SY
    Genes Dis; 2016 Sep; 3(3):198-210. PubMed ID: 30258889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Temozolomide: mechanisms of action, repair and resistance.
    Zhang J; Stevens MF; Bradshaw TD
    Curr Mol Pharmacol; 2012 Jan; 5(1):102-14. PubMed ID: 22122467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overcoming temozolomide resistance in glioblastoma via dual inhibition of NAD+ biosynthesis and base excision repair.
    Goellner EM; Grimme B; Brown AR; Lin YC; Wang XH; Sugrue KF; Mitchell L; Trivedi RN; Tang JB; Sobol RW
    Cancer Res; 2011 Mar; 71(6):2308-17. PubMed ID: 21406402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PARP inhibition suppresses the emergence of temozolomide resistance in a model system.
    Yuan AL; Meode M; Tan M; Maxwell L; Bering EA; Pedersen H; Willms J; Liao J; Black S; Cairncross JG; Blough MD
    J Neurooncol; 2020 Jul; 148(3):463-472. PubMed ID: 32562246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Certain imidazotetrazines escape O6-methylguanine-DNA methyltransferase and mismatch repair.
    Zhang J; Stevens MF; Hummersone M; Madhusudan S; Laughton CA; Bradshaw TD
    Oncology; 2011; 80(3-4):195-207. PubMed ID: 21720182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tubeimoside-I sensitizes temozolomide-resistant glioblastoma cells to chemotherapy by reducing MGMT expression and suppressing EGFR induced PI3K/Akt/mTOR/NF-κB-mediated signaling pathway.
    Tang Q; Cao H; Tong N; Liu Y; Wang W; Zou Y; Xu L; Zeng Z; Xu W; Yin Z; Ma W; Wang Q
    Phytomedicine; 2022 May; 99():154016. PubMed ID: 35278900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist.
    Wang H; Cai S; Bailey BJ; Reza Saadatzadeh M; Ding J; Tonsing-Carter E; Georgiadis TM; Zachary Gunter T; Long EC; Minto RE; Gordon KR; Sen SE; Cai W; Eitel JA; Waning DL; Bringman LR; Wells CD; Murray ME; Sarkaria JN; Gelbert LM; Jones DR; Cohen-Gadol AA; Mayo LD; Shannon HE; Pollok KE
    J Neurosurg; 2017 Feb; 126(2):446-459. PubMed ID: 27177180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overcoming Temozolomide Resistance in Glioblastoma via Enhanced NAD
    Li J; Koczor CA; Saville KM; Hayat F; Beiser A; McClellan S; Migaud ME; Sobol RW
    Cancers (Basel); 2022 Jul; 14(15):. PubMed ID: 35892832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Restoration of Temozolomide Sensitivity by PARP Inhibitors in Mismatch Repair Deficient Glioblastoma is Independent of Base Excision Repair.
    Higuchi F; Nagashima H; Ning J; Koerner MVA; Wakimoto H; Cahill DP
    Clin Cancer Res; 2020 Apr; 26(7):1690-1699. PubMed ID: 31900275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacologic disruption of base excision repair sensitizes mismatch repair-deficient and -proficient colon cancer cells to methylating agents.
    Liu L; Taverna P; Whitacre CM; Chatterjee S; Gerson SL
    Clin Cancer Res; 1999 Oct; 5(10):2908-17. PubMed ID: 10537360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression.
    Perazzoli G; Prados J; Ortiz R; Caba O; Cabeza L; Berdasco M; Gónzalez B; Melguizo C
    PLoS One; 2015; 10(10):e0140131. PubMed ID: 26447477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N3-substituted temozolomide analogs overcome methylguanine-DNA methyltransferase and mismatch repair precipitating apoptotic and autophagic cancer cell death.
    Zhang J; Hummersone M; Matthews CS; Stevens MF; Bradshaw TD
    Oncology; 2015; 88(1):28-48. PubMed ID: 25277441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Temozolomide-resistant Glioblastoma Depends on HDAC6 Activity Through Regulation of DNA Mismatch Repair.
    Kim GW; Lee DH; Yeon SK; Jeon YH; Yoo J; Lee SW; Kwon SH
    Anticancer Res; 2019 Dec; 39(12):6731-6741. PubMed ID: 31810938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ursolic acid attenuates temozolomide resistance in glioblastoma cells by downregulating O(6)-methylguanine-DNA methyltransferase (MGMT) expression.
    Zhu Z; Du S; Ding F; Guo S; Ying G; Yan Z
    Am J Transl Res; 2016; 8(7):3299-308. PubMed ID: 27508051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. β-catenin contributes to cordycepin-induced MGMT inhibition and reduction of temozolomide resistance in glioma cells by increasing intracellular reactive oxygen species.
    Bi Y; Li H; Yi D; Bai Y; Zhong S; Liu Q; Chen Y; Zhao G
    Cancer Lett; 2018 Oct; 435():66-79. PubMed ID: 30081068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NF-κB inhibitor reverses temozolomide resistance in human glioma TR/U251 cells.
    Wang X; Jia L; Jin X; Liu Q; Cao W; Gao X; Yang M; Sun B
    Oncol Lett; 2015 Jun; 9(6):2586-2590. PubMed ID: 26137111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bortezomib overcomes MGMT-related resistance of glioblastoma cell lines to temozolomide in a schedule-dependent manner.
    Vlachostergios PJ; Hatzidaki E; Befani CD; Liakos P; Papandreou CN
    Invest New Drugs; 2013 Oct; 31(5):1169-81. PubMed ID: 23645448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of TMZ resistance-associated histone post-translational modifications in glioblastoma using multi-omics data.
    Ye L; Gu L; Wang Y; Xing H; Li P; Guo X; Wang Y; Ma W
    CNS Neurosci Ther; 2024 Mar; 30(3):e14649. PubMed ID: 38448295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GADD45A plays a protective role against temozolomide treatment in glioblastoma cells.
    Wang HH; Chang TY; Lin WC; Wei KC; Shin JW
    Sci Rep; 2017 Aug; 7(1):8814. PubMed ID: 28821714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acquired temozolomide resistance in human glioblastoma cell line U251 is caused by mismatch repair deficiency and can be overcome by lomustine.
    Stritzelberger J; Distel L; Buslei R; Fietkau R; Putz F
    Clin Transl Oncol; 2018 Apr; 20(4):508-516. PubMed ID: 28825189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 51.